Incyclix Bio
Latest round
- Series B
Last raised
- Apr 2026
Total raised
- $28M
Investors
- 7
About Incyclix Bio
Incyclix Bio, LLC is a biotechnology company specializing in the development of innovative oncology therapeutics, particularly focused on precision treatments for various cancers through targeted therapeutic strategies. Founded in 2020 in the United States, Incyclix Bio, LLC develops oncology solutions, including its lead product INX-315, a CDK2 inhibitor currently in clinical trials.Incyclix Bio focuses on developing innovative oncology therapeutics that target the aberrant proliferation characteristic of various cancers. Their lead product, INX-315, is a selective inhibitor of cyclin-dependent kinase 2 (CDK2) and is currently undergoing clinical trials aimed at treating ovarian, breast, and lung cancers, particularly in patients resistant to existing treatments.Incyclix Bio's revenue model is based on partnerships and clinical trial agreements, which support the commercialization of INX-315 and other products. The company engages in business-to-business transactions with healthcare institutions and pharmaceutical partners. Revenue is expected to be generated through successful clinical trial milestones and regulatory approvals, with pricing strategies potentially including direct sales to healthcare facilities and subscription models for access to therapies, though specific pricing details are confidential.
Who invested in Incyclix Bio
7 investors across 3 rounds
See all investors in Incyclix Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Incyclix Bio
Who invested in Incyclix Bio?
Incyclix Bio has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Incyclix Bio raised?
Incyclix Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Incyclix Bio last raise money?
Incyclix Bio's most recent round on record is a Series B, in Apr 2026.
What does Incyclix Bio do?
Incyclix Bio, LLC is a biotechnology company specializing in the development of innovative oncology therapeutics, particularly focused on precision treatments for various cancers through targeted therapeutic strategies.
Where is Incyclix Bio headquartered?
Incyclix Bio is headquartered in Research Triangle Park, US.
Which VCs invest in companies like Incyclix Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Incyclix Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Incyclix Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.